PCMN
PFE icon

Paradigm Capital Management (Nevada)’s Pfizer PFE Stock Holding History

Paradigm Capital Management (Nevada)’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$523K Sell
21,699
-557
-3% -$14.6K 0.45% 44
2026
Q1 		$625K Sell
22,256
-153
-0.7% -$4.07K 0.57% 38
2025
Q4 		$558K Sell
22,409
-1,392
-6% -$35.1K 0.52% 40
2025
Q3 		$607K Sell
23,801
-15,494
-39% -$382K 0.6% 35
2025
Q2 		$953K Sell
39,295
-21,686
-36% -$506K 0.94% 30
2025
Q1 		$1.54M Sell
60,981
-25,097
-29% -$657K 1.58% 20
2024
Q4 		$2.28M Sell
86,078
-6,564
-7% -$178K 2.13% 12
2024
Q3 		$2.68M Buy
+92,642
New +$2.7M 2.57% 9
2022
Q4 		$2.82M Buy
55,038
+1,183
+2% +$56.7K 4.13% 6
2022
Q3 		$2.36M Buy
53,855
+135
+0.3% +$6.56K 3.14% 7
2022
Q2 		$2.82M Sell
53,720
-287
-0.5% -$14.6K 3.54% 7
2022
Q1 		$2.8M Buy
54,007
+304
+0.6% +$15.8K 2.82% 9
2021
Q4 		$3.17M Buy
+53,703
New +$2.66M 3.15% 8

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Paradigm Capital Management (Nevada)'s PFE Position: Q2 2026 in Review

Paradigm Capital Management (Nevada) reduced its Pfizer (PFE) stake by 2.5% in Q2 2026, selling an estimated $14.6K and leaving 21,699 shares worth $523K. The position accounts for 0.45% of the portfolio, ranked #44.

Paradigm Capital Management (Nevada) first reported a position in PFE in Q4 2021 and has held it in 13 quarters since. The position peaked at $3.17M in Q4 2021. 2,834 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Paradigm Capital Management (Nevada) held 21,699 shares of Pfizer worth $523K as of Q2 2026.
  • Paradigm Capital Management (Nevada) sold 557 Pfizer shares in Q2 2026, an estimated $14.6K.
  • Pfizer made up 0.45% of Paradigm Capital Management (Nevada)'s portfolio in Q2 2026, its #44 holding.
  • Paradigm Capital Management (Nevada) first reported a position in Pfizer in Q4 2021 and has held it in 13 quarters since.
  • Paradigm Capital Management (Nevada)'s Pfizer position peaked at $3.17M in Q4 2021.
  • 2,834 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Paradigm Capital Management (Nevada)'s 13F filing for Q2 2026, filed 14 Aug 2026.